Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Larkspur Biosciences launches with combined seed and series A funding of $35.5

by Laura Howes
June 4, 2023 | A version of this story appeared in Volume 101, Issue 18

 

Larkspur Biosciences, which develops cancer immunotherapies, has launched with $35.5 million in combined seed and series A funding. The biotech, which has an all-female leadership team, was cofounded by Vijay Kuchroo of Harvard University, Lewis Cantley of Dana-Farber Cancer Institute, and Nathanael Gray of Stanford University. The firm says it intends to develop precision immunotherapies to tackle different cancers with the same immune evasion phenotypes, with a first focus on colorectal cancer.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.